I think the sell off is a knee jerk reaction due to discontinuing there Yosprala drug. The increase in the quarterly loss was the right off of the fair value of Yosprala. Otherwise, we might have missed the projected loss by only .03. Next quarter should be much better. JMHO
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.